Posts by Follicle Thought
Interview with Stemson Therapeutics CEO Geoff Hamilton
Follicle Thought is very pleased to share this exclusive interview with the CEO of Stemson Therapeutics, Geoff Hamilton. Follicle Thought: Hi Geoff, thank you for doing this interview with Follicle Thought. To start, could you please tell us about how you met Dr. Alexey Terskikh and went on to become Stemson’s CEO? Geoff Hamilton: Well, thank…
Read MoreKintor’s KX-826 Pyrilutamide Meets Goal In Phase 2 Trial
Kintor Pharmaceutical of China brings us some timely good news today regarding its lead candidate drug KX-826 for the treatment of androgenetic alopecia. Phase 3 Will Be Soon A well respected company in the hair growth industry, Kintor Pharmaceutical, continues to outpace the competition. In a press release issued today, the company announced that KX-826…
Read MoreQ3 2021 New Companies: AddPharma, Novaliq, and Rizn
This article covers a few companies not previously discussed online and recent happenings in hair growth related news. AddPharma of Korea Where else would new hair growth medicine be coming out of but Korea? In the case of AddPharma, it’s a mixture of “old and new”, but we’ll take it. AddPharma is a pharmaceutical company…
Read MoreAlopecia Areata Treatment Pipeline 2023
In this article we will cover the most prominent therapeutic candidates in the alopecia areata treatment industry in 2023. Frontrunners To Market In June 2022, Eli Lilly/Incyte received the FDA’s first ever approval for a systemic treatment for alopecia areata with their drug Olumiant. Alopecia areata, an auto-immune disorder which results in patchy and sometimes…
Read MoreStemson Therapeutics Raises $15M To Bolster Hair Regeneration Efforts
The company founded on Alexey Terskikh’s hair multiplication research at the Sanford Burnham Prebys Institute has not had a problem raising capital since its inception a few years ago. In a press release issued today, July, 15, 2021, Stemson Therapeutics announced the closing of a $15 million Series A financing round. DCVC-Bio and Genoa Ventures…
Read MoreDavid Sinclair Is Working On Hair Regeneration
Perhaps the world’s most famous aging researcher, Dr. David Sinclair of Harvard University, recently revealed that his lab is working on an advanced method for hair restoration. The Sinclair Lab at Harvard Medical School Hair Growth Research Located in Boston, MA, The Sinclair Lab conducts cutting-edge research on the mechanisms of biological aging. The laboratory’s…
Read MoreTurn Biotechnologies: mRNA Hair Growth Therapy
Today, I am pleased to introduce yet another company entering the hair growth treatment industry, Turn Biotechnologies. The company is creating therapies which restore human cells to a more youthful state and has a program targeting skin and hair. Turn Biotechnologies is one of the latest companies to make waves in the anti-aging/aging-reversal sector. The…
Read MoreTechnoDerma Medicines Enters Clinical Trial & More
This article continues the recent trend of new company announcements within the hair growth treatment industry. Even better, today’s news involves a new drug entering a phase 1 clinical trial in the US. New Drug Candidate TDM-105795 TechnoDerma Medicines Inc. of China is an early-stage biotech company based in the Zhejiang Province of China. The…
Read MoreVerteporfin Could Create Scarless Hair Transplant Surgery
New research from Stanford University may have uncovered a new useful application for hair restoration surgery. Stanford Stops The Engrailed-1 Last month in April, a research team from Stanford University headed by Dr. Michael Longaker, published a study on scarless wound healing which captured mainstream attention. The peer-reviewed study titled “Preventing Engrailed-1 activation in fibroblasts yields…
Read MoreFollicum Shares Results From Phase 2a Trial Of Topical FOL-005
On May 6, 2021 the Swedish biotech company Follicum announced results from its pivotal phase 2 trial which represented the first time its candidate peptide FOL-005 was tested topically to treat male pattern baldness. FOL-005 Grew Hair, But Not Quite Enough To keep things succinct, FOL-005 did not reach its goal in the phase 2…
Read More